REGENXBIO (NASDAQ:RGNX) Stock Rating Upgraded by Raymond James

REGENXBIO (NASDAQ:RGNX) was upgraded by research analysts at Raymond James to a “moderate buy” rating in a note issued to investors on Thursday,Zacks.com reports.

Several other equities research analysts have also weighed in on RGNX. HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of REGENXBIO in a research report on Wednesday, January 15th. Chardan Capital reaffirmed a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a research report on Wednesday, November 20th. Morgan Stanley reissued an “overweight” rating and set a $22.00 price objective on shares of REGENXBIO in a research note on Friday, November 15th. Royal Bank of Canada reiterated an “outperform” rating and set a $30.00 target price on shares of REGENXBIO in a report on Tuesday, January 21st. Finally, StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, REGENXBIO presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.64.

REGENXBIO Price Performance

Shares of NASDAQ RGNX opened at $8.21 on Thursday. REGENXBIO has a 1 year low of $6.56 and a 1 year high of $28.80. The stock has a market capitalization of $406.72 million, a P/E ratio of -1.63 and a beta of 1.29. The company’s 50-day moving average is $8.11 and its 200 day moving average is $10.10.

Institutional Trading of REGENXBIO

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC increased its stake in shares of REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 2,510 shares in the last quarter. FMR LLC boosted its position in shares of REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,656 shares during the last quarter. nVerses Capital LLC grew its stake in REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 2,200 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 3,720 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new stake in shares of REGENXBIO in the third quarter worth about $140,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.